AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21906396 — intervention group
Group type: COMPARATOR
Intervention: Standard laboratory service
Number of subjects: 239
Study 19241855 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for tumor combined with lymph dissection D2 and cytoreduction (R1 and R2)
Number of subjects: 587
Study 19241855 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for tumor combined with splenectomy
Number of subjects: 587
Study 19241855 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen re-plantation into the round ligament of the liver
Number of subjects: 587
Study 19241855 — intervention group
Group type: COMPARATOR
Intervention: Controls (standard, palliative and diagnostic operations)
Number of subjects: 587
Study 16314076 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 10.0001‐Hz rTMS to the left temporoparietal cortex
Number of subjects: 24
Study 16314076 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 24
Study 12683708 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level energy laser therapy (LLLT) with Gallium Arsenide laser irradiation at 890 nm
Number of subjects: 130
Study 12683708 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation (control)
Number of subjects: 130
Study 11531635 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mcg misoprostol per rectum
Number of subjects: 64
Study 10181070 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton plus usual asthma care
Number of subjects: 2947
Study 10181070 — intervention group
Group type: COMPARATOR
Intervention: Usual asthma care alone
Number of subjects: 2947
Study 7917928 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2a (IFN-alpha) 6 MU every 48 h
Number of subjects: 19
Study 7917928 — intervention group
Group type: COMPARATOR
Intervention: Control (no IFN-alpha)
Number of subjects: 19
Study 3254763 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion (0‐54 ng min‐1 kg‐1) for 15 min per dose
Number of subjects: 8
Study 31878820 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 362
Study 31878820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 31356558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nano vitamin D (60,000 IU/d for 8 days)
Number of subjects: 0
Study 31356558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31356558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nano vitamin D
Number of subjects: 0
Study 28198572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided rectus sheath block with 0.2 ml·kg‐1 of 0.375% ropivacaine per side
Number of subjects: 34
Study 28198572 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration with 0.2 ml·kg‐1 of 0.75% ropivacaine
Number of subjects: 34
Study 28198572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided rectus sheath block
Number of subjects: 34
Study 28198572 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration
Number of subjects: 34
Study 26258177 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive flowable composite resin (SAFC) - Fusio Liquid Dentin
Number of subjects: 80
Study 26258177 — intervention group
Group type: COMPARATOR
Intervention: Nanohybrid composite (E&Ra/nanoC) - G-aenial with three-step etch-and-rinse adhesive system (Optibond FL)
Number of subjects: 80
Study 26258177 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 23931889 — intervention group
Group type: EXPERIMENTAL
Intervention: HA330 hemoperfusion treatment (N=25)
Number of subjects: 46
Study 23931889 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (N=21)
Number of subjects: 46
Study 21757141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dan-Chi-Liu-Wei combination (DCLWC)
Number of subjects: 53
Study 21757141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 19281572 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous shunting
Number of subjects: 0
Study 19281572 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16881780 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse (CSA)
Number of subjects: 827
Study 16881780 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use (for men)
Number of subjects: 827
Study 16881780 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use (for women)
Number of subjects: 827
Study 16881780 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence (for women)
Number of subjects: 827
Study 15572490 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 10 mg ephedrine followed by a continuous infusion for 60 minutes of 20 mg ephedrine
Number of subjects: 145
Study 15572490 — intervention group
Group type: COMPARATOR
Intervention: No ephedrine (control group)
Number of subjects: 145
Study 11357168 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 472
Study 11357168 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 472
Study 11357168 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/d of recombinant human interleukin-1 receptor antagonist (IL-1ra)
Number of subjects: 472
Study 11357168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 472
Study 9146603 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile vibratory stimulation
Number of subjects: 11
Study 9146603 — intervention group
Group type: COMPARATOR
Intervention: Electroejaculation
Number of subjects: 11
Study 7525422 — intervention group
Group type: EXPERIMENTAL
Intervention: Total peritoneal fluid TAP concentration > or = nmol
Number of subjects: 22
Study 7525422 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fluid volume > 20 ml or free fluid colour > grade 5 on the Leeds chart
Number of subjects: 22
Study 30349139 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium L-glutamate (MSG) 0.9 g/dose, thrice daily
Number of subjects: 159
Study 30349139 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.26 g/dose, thrice daily (Control group)
Number of subjects: 159
Study 29549464 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 5 mg/kg/day for 4 months
Number of subjects: 70
Study 29549464 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study 27436681 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 78
Study 27436681 — intervention group
Group type: COMPARATOR
Intervention: Cook cervical ripening balloon
Number of subjects: 78
Study 24417452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group using time aids
Number of subjects: 47
Study 24417452 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 47
Study 22472578 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 43
Study 22472578 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 43
Study 22472578 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 19809829 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (7 days)
Number of subjects: 450
Study 19809829 — intervention group
Group type: EXPERIMENTAL
Intervention: OHP (7 days)
Number of subjects: 450
Study 19809829 — intervention group
Group type: EXPERIMENTAL
Intervention: OHP (14 days)
Number of subjects: 450
Study 18976959 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasomotor symptoms reported at 3-month follow-up
Number of subjects: 3964
Study 18976959 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint symptoms reported at 3-month follow-up
Number of subjects: 3964
Study 16463821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 0
Study 14725500 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes video of a dentist explaining what an injection will feel like and proposing hand raising as a signal mechanism
Number of subjects: 101
Study 14725500 — intervention group
Group type: COMPARATOR
Intervention: 2 minutes video of Disneyland
Number of subjects: 101
Study 11864504 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent inactivated vaccine
Number of subjects: 657
Study 7573627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed pamphlet and letter
Number of subjects: 2053
Study 7573627 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call
Number of subjects: 2053
Study 7573627 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit outreach intervention
Number of subjects: 2053
Study 7573627 — intervention group
Group type: COMPARATOR
Intervention: Usual method of informing at Medicaid intake (Control)
Number of subjects: 2053
Study 1936009 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 units of Anisoylated Plasminogen Streptokinase Activator Complex (APSAC, eminase) intravenously by a mobile intensive care unit (MICU)
Number of subjects: 62
Study 1936009 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital period
Number of subjects: 62
Study 1936009 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay
Number of subjects: 62
Study 6124906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazadinium (1 mg/kg)
Number of subjects: 40
Study 6124906 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study 6124906 — intervention group
Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 40
Study 31434774 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional methods plus VR videos
Number of subjects: 322
Study 31434774 — intervention group
Group type: COMPARATOR
Intervention: Conventional patient education
Number of subjects: 322
Study 29609570 — intervention group
Group type: COMPARATOR
Intervention: Control condition: PE teachers encouraged students to participate in PA during leisure time without providing persuasive messages.
Number of subjects: 171
Study 29609570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition: PE teachers delivered persuasive messages targeting salient benefits and barriers associated with PA during the last 5 to 10 minutes of each PE lesson.
Number of subjects: 171
Study 26475166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 15 mL
Number of subjects: 0
Study 26475166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 15 mL with 1:200,000 epinephrine
Number of subjects: 0
Study 26475166 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine 15 mL
Number of subjects: 0
Study 26475166 — intervention group
Group type: COMPARATOR
Intervention: Comparison of warm sensation thresholds on one dermatome at 24 hr
Number of subjects: 0
Study 25017575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2% plus adrenaline with sodium bicarbonate 1.4%
Number of subjects: 100
Study 25017575 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.9%
Number of subjects: 100
Study 23018435 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (intensified arm, n = 30)
Number of subjects: 44
Study 23018435 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (control arm, n = 14)
Number of subjects: 44
Study 20386508 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous arginine vasopressin infusion (AVP) at doses of 0.033 IU/min and 0.067 IU/min
Number of subjects: 39
Study 20386508 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in copeptin levels during AVP therapy
Number of subjects: 39
Study 17084411 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAM
Number of subjects: 30
Study 17084411 — intervention group
Group type: EXPERIMENTAL
Intervention: LTD
Number of subjects: 30
Study 17084411 — intervention group
Group type: EXPERIMENTAL
Intervention: LD
Number of subjects: 30
Study 17084411 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 16278257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg once daily
Number of subjects: 982
Study 16278257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 982
Study 12404707 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg of scopolamine (SP)
Number of subjects: 36
Study 12404707 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg of scopolamine (SP)
Number of subjects: 36
Study 12404707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 12569761 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger dose of ribavirin
Number of subjects: 155
Study 12569761 — intervention group
Group type: COMPARATOR
Intervention: Routine therapeutic dose of ribavirin (Control)
Number of subjects: 155
Study 7804972 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms three times per day and tamoxifen 10 mg twice daily
Number of subjects: 12
Study 7804972 — intervention group
Group type: COMPARATOR
Intervention: Historic cohort (untreated patients)
Number of subjects: 12
Study 7804972 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-tamoxifen group
Number of subjects: 12
Study 2230868 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose megestrol acetate (MA), 800 mg/d
Number of subjects: 172
Study 2230868 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose megestrol acetate (MA), 160 mg/d
Number of subjects: 172
Study 466964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (10 fractions)
Number of subjects: 24
Study 466964 — intervention group
Group type: COMPARATOR
Intervention: Air (15 or 20 fractions)
Number of subjects: 24
Study 30654454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-convective volume postdilution hemodiafiltration
Number of subjects: 15
Study 30654454 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis
Number of subjects: 15
Study 30654454 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis
Number of subjects: 15
Study 30073605 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback Training (NFT)
Number of subjects: 20
Study 30073605 — intervention group
Group type: COMPARATOR
Intervention: Control condition (mock NFT)
Number of subjects: 20
Study 27067670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing intervention (signs and enhancement of stairwell aesthetics)
Number of subjects: 1328
Study 27067670 — intervention group
Group type: COMPARATOR
Intervention: Control site (no intervention)
Number of subjects: 1328
Study 27067670 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing intervention (after intervention)
Number of subjects: 1328
Study 25117820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 21997224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 166
Study 21997224 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation
Number of subjects: 166
Study 20186887 — intervention group
Group type: EXPERIMENTAL
Intervention: High PSWT (PD 200 μsec, PRR 800 Hz, MP 24 W, 10 minutes)
Number of subjects: 31
Study 20186887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PSWT (PD 100 μsec, PRR 200 Hz, MP 3 W, 10 minutes)
Number of subjects: 31
Study 20186887 — intervention group
Group type: COMPARATOR
Intervention: Placebo PSWT (PD 20 μsec, PRR 50 Hz, MP 0.05 W, 10 minutes)
Number of subjects: 31
Study 20186887 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no treatment, 10 minutes)
Number of subjects: 31
Study 18317973 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 3212
Study 18317973 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 3212
Study 15977265 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 410
Study 14624186 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment
Number of subjects: 131
Study 10774806 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 Immunogen (REMUNE)
Number of subjects: 0
Study 8858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg with grapefruit juice (GraMid)
Number of subjects: 0
Study 8858279 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 10 mg with water (Mid)
Number of subjects: 0
Study 8858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg with grapefruit juice (GraTrz)
Number of subjects: 0
Study 8858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg with erythromycin (EryMid)
Number of subjects: 0
Study 8858279 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg alone
Number of subjects: 0
Study 8858279 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice (Gra)
Number of subjects: 0
Study 1454971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 1454971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4061978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (320 micrograms)
Number of subjects: 24
Study 4061978 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (180 micrograms)
Number of subjects: 24
Study 4061978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31547736 — intervention group
Group type: EXPERIMENTAL
Intervention: CPX-351 (vyxeos)
Number of subjects: 0
Study 31547736 — intervention group
Group type: COMPARATOR
Intervention: 7+3 regimen (cytarabine and anthracycline)
Number of subjects: 0
Study 28816693 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-frequency matching therapy
Number of subjects: 0
Study 28816693 — intervention group
Group type: COMPARATOR
Intervention: Single-frequency matching therapy
Number of subjects: 0
Study 26908630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% rh-FGF-2/β-TCP
Number of subjects: 88
Study 26908630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% rh-FGF-2/β-TCP
Number of subjects: 88
Study 26908630 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% rh-FGF-2/β-TCP
Number of subjects: 88
Study 26908630 — intervention group
Group type: COMPARATOR
Intervention: β-TCP alone (control)
Number of subjects: 88
Study 24257717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 15 mg/day
Number of subjects: 608
Study 24257717 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Number of subjects: 608
Study 24257717 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 608
Study 24257717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study 22100462 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional-bridge progression
Number of subjects: 51
Study 22100462 — intervention group
Group type: COMPARATOR
Intervention: Suspension-exercise-bridge progression
Number of subjects: 51
Study 19615160 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional serrated adenoma (TSA)
Number of subjects: 75
Study 19615160 — intervention group
Group type: COMPARATOR
Intervention: Conventional adenoma
Number of subjects: 75
Study 19615160 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrated carcinoma
Number of subjects: 75
Study 19615160 — intervention group
Group type: COMPARATOR
Intervention: Non‐serrated adenocarcinoma (N‐Sca)
Number of subjects: 75
Study 19615160 — intervention group
Group type: COMPARATOR
Intervention: Villous adenoma (AD)
Number of subjects: 75
Study 17307663 — intervention group
Group type: EXPERIMENTAL
Intervention: CART with bootstrap aggregation
Number of subjects: 144
Study 17307663 — intervention group
Group type: COMPARATOR
Intervention: Expert evaluation
Number of subjects: 144
Study 16138217 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple grape juice (GJ), 500 ml/day for 14 days
Number of subjects: 16
Study 16138217 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (RW), 250 ml/day for 14 days
Number of subjects: 16
Study 16138217 — intervention group
Group type: COMPARATOR
Intervention: Control group (24 normal subjects)
Number of subjects: 16
Study 12045521 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical candidates with chronic low back pain
Number of subjects: 294
Study 12045521 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with back pain
Number of subjects: 294
Study 12045521 — intervention group
Group type: COMPARATOR
Intervention: Control subjects free of back pain
Number of subjects: 294
Study 12017006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release formulation of isosorbide-5-mononitrate (40 mg, qd)
Number of subjects: 10
Study 12017006 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation of isosorbide-5-mononitrate (20 mg, bid)
Number of subjects: 10
Study 8615057 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 22
Study 8615057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2378185 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms PGE2 gel
Number of subjects: 50
Study 2378185 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 50
Study 348558 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 0
Study 348558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30076254 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to web-based patient information
Number of subjects: 148
Study 30076254 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no access to web-based information)
Number of subjects: 148
Study 28080250 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 150 mg subcutaneous
Number of subjects: 0
Study 28080250 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular interferon beta-1a 30 µg
Number of subjects: 0
Study 28080250 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 0
Study 26200977 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast irradiation plus regional nodal irradiation (nodal-irradiation group)
Number of subjects: 1832
Study 26200977 — intervention group
Group type: COMPARATOR
Intervention: Whole-breast irradiation alone (control group)
Number of subjects: 1832
Study 24438351 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling alone
Number of subjects: 0